1. Chao TF, Liu CJ, Tuan TC, et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study. Chest. 2018; 153:453–466.
2. Lee SR, Choi EK, Han KD, Cha MJ, Oh S. Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. Int J Cardiol. 2017; 236:226–231.
3. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014; 111:789–797.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22:983–988.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009; 40:235–240.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med. 2002; 162:541–550.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Henninger N, Goddeau RP Jr, Karmarkar A, Helenius J, McManus DD. Atrial fibrillation is associated with a worse 90-day outcome than other cardioembolic stroke subtypes. Stroke. 2016; 47:1486–1492.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Perera KS, Vanassche T, Bosch J, et al. Global survey of the frequency of atrial fibrillation-associated stroke: embolic stroke of undetermined source global registry. Stroke. 2016; 47:2197–2202.
9. Tomita H, Hagii J, Metoki N, et al. Impact of sex difference on severity and functional outcome in patients with cardioembolic stroke. J Stroke Cerebrovasc Dis. 2015; 24:2613–2618.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Kim D, Yang PS, Jang E, et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. Heart. 2018.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137:263–272.
12. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007; 147:590–592.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol. 2015; 180:246–254.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–992.
15. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369:2093–2104.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–891.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–1151.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Cha MJ, Choi EK, Han KD, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation. Stroke. 2017; 48:3040–3048.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013; 44:1891–1896.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Wong KS, Hu DY, Oomman A, et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke. 2014; 45:1739–1747.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Yamashita T, Koretsune Y, Yang Y, et al. Edoxaban vs. warfarin in East Asian patients with atrial fibrillation - an ENGAGE AF-TIMI 48 subanalysis. Circ J. 2016; 80:860–869.
22. Goto S, Zhu J, Liu L, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J. 2014; 168:303–309.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37:2893–2962.
24. Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017; 33:345–367.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Jones C, Pollit V, Fitzmaurice D, Cowan C; Guideline Development Group. The management of atrial fibrillation: summary of updated NICE guidance. BMJ. 2014; 348:g3655.
![crossref](/image/icon/bnr_ref_cross.gif)
26. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64:e1–e76.
27. Chao TF, Liu CJ, Tuan TC, et al. Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: which scoring system should be used for Asians? Heart Rhythm. 2016; 13:46–53.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Xiong Q, Chen S, Senoo K, Proietti M, Hong K, Lip GY. The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: a systemic review and meta-analysis. Int J Cardiol. 2015; 195:237–242.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Kim TH, Yang PS, Kim D, et al. CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean nationwide cohort study. Stroke. 2017; 48:2984–2990.
30. Kang SH, Choi EK, Han KD, et al. Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants - Korean nationwide population-based study. Circ J. 2017; 81:1158–1164.
31. Chao TF, Liu CJ, Wang KL, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in ‘low-risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol. 2014; 64:1658–1665.
32. Chan PH, Lau CP, Tse HF, Chiang CE, Siu CW. CHA2DS2-VASc recalibration with an additional age category (50–64 Years) enhances stroke risk stratification in Chinese patients with atrial fibrillation. Can J Cardiol. 2016; 32:1381–1387.
33. Chao TF, Wang KL, Liu CJ, et al. Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan. J Am Coll Cardiol. 2015; 66:1339–1347.
34. Chao TF, Lip GY, Liu CJ, et al. Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study. Stroke. 2016; 47:2462–2469.
35. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015; 65:635–642.
36. Hung Y, Chao TF, Liu CJ, et al. Is an oral anticoagulant necessary for young atrial fibrillation patients with a CHA2DS2-VASc score of 1 (men) or 2 (women)? J Am Heart Assoc. 2016; 5:e003839.
![crossref](/image/icon/bnr_ref_cross.gif)
37. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011; 4:14–21.
38. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J. 2014; 78:1997–2021.
39. Chiang CE, Wu TJ, Ueng KC, et al. 2016 guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc. 2016; 115:893–952.
![crossref](/image/icon/bnr_ref_cross.gif)
40. Jung BC, Kim NH, Nam GB, et al. The Korean Heart Rhythm Society's 2014 statement on antithrombotic therapy for patients with nonvalvular atrial fibrillation: Korean Heart Rhythm Society. Korean Circ J. 2015; 45:9–19.
![crossref](/image/icon/bnr_ref_cross.gif)
41. Lee JM, Joung B, Cha MJ, et al. 2018 KHRS guidelines for stroke prevention therapy in Korean patients with nonvalvular atrial fibrillation. Korean J Med. 2018; 93:87–109.
![crossref](/image/icon/bnr_ref_cross.gif)
42. Chao TF, Lip GY, Liu CJ, et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol. 2018; 71:122–132.
![crossref](/image/icon/bnr_ref_cross.gif)
43. Yoon M, Yang PS, Jang E, et al. Dynamic changes of CHA2DS2-VASc score and the risk of ischaemic stroke in Asian patients with atrial fibrillation: a nationwide cohort study. Thromb Haemost. 2018.
![crossref](/image/icon/bnr_ref_cross.gif)
44. Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost. 2016; 14:1711–1714.
![crossref](/image/icon/bnr_ref_cross.gif)
45. Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review. Patient. 2017; 10:17–37.
![crossref](/image/icon/bnr_ref_cross.gif)
46. Guo Y, Zhu H, Chen Y, Lip GY. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med. 2018; 131:185–192.
![crossref](/image/icon/bnr_ref_cross.gif)
47. Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldán V, Lip GY, Marín F. Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial. Thromb Haemost. 2017; 117:2261–2266.
![crossref](/image/icon/bnr_ref_cross.gif)
48. Chao TF, Lip GY, Lin YJ, et al. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. Int J Cardiol. 2018; 254:157–161.
![crossref](/image/icon/bnr_ref_cross.gif)
49. Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016; 387:2302–2311.
![crossref](/image/icon/bnr_ref_cross.gif)
50. O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015; 36:3258–3264.
51. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation) study. J Am Coll Cardiol. 2011; 58:395–401.
52. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138:1093–1100.
53. Guo YT, Zhang Y, Shi XM, et al. Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: the Beijing PLA Hospital Atrial Fibrillation Project. Sci Rep. 2016; 6:31755.
![crossref](/image/icon/bnr_ref_cross.gif)
54. Chao TF, Lip GY, Lin YJ, et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost. 2018; 118:768–777.
![crossref](/image/icon/bnr_ref_cross.gif)
55. Park CS, Choi EK, Kim HM, et al. Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. Heart Rhythm. 2017; 14:501–507.
![crossref](/image/icon/bnr_ref_cross.gif)
56. Zoppellaro G, Granziera S, Bertozzo G, et al. Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation. Thromb Haemost. 2017; 117:1828–1830.
![crossref](/image/icon/bnr_ref_cross.gif)
57. Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017; 117:1448–1454.
![crossref](/image/icon/bnr_ref_cross.gif)
58. Wu S, Yang YM, Zhu J, et al. Meta-analysis of efficacy and safety of new oral anticoagulants compared with uninterrupted vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol. 2016; 117:926–934.
![crossref](/image/icon/bnr_ref_cross.gif)
59. Cardoso R, Knijnik L, Bhonsale A, et al. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm. 2018; 15:107–115.
![crossref](/image/icon/bnr_ref_cross.gif)
60. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GY. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017; 48:2494–2503.
61. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383:955–962.
![crossref](/image/icon/bnr_ref_cross.gif)
62. Li YG, Pastori D, Lip GY. Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. Ann Med. 2018; 50:288–302.
![crossref](/image/icon/bnr_ref_cross.gif)
63. Shimada YJ, Yamashita T, Koretsune Y, et al. Effects of regional differences in Asia on efficacy and safety of edoxaban compared with warfarin--insights from the ENGAGE AF-TIMI 48 trial. Circ J. 2015; 79:2560–2567.
64. Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J. 2012; 76:2104–2111.
65. Wang KL, Lip GY, Lin SJ, Chiang CE. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke. 2015; 46:2555–2561.
66. Kohsaka S, Katada J, Saito K, Terayama Y. Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data. Curr Med Res Opin. 2018; 1–8.
![crossref](/image/icon/bnr_ref_cross.gif)
67. Lee KH, Park HW, Lee N, et al. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation. Europace. 2017; 19:iv1–9.
![crossref](/image/icon/bnr_ref_cross.gif)
68. Hong KS, Kwon SU, Lee SH, et al. Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke: a randomized clinical trial. JAMA Neurol. 2017; 74:1206–1215.
69. Dillinger JG, Aleil B, Cheggour S, et al. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. Arch Cardiovasc Dis. 2018; 111:85–94.
![crossref](/image/icon/bnr_ref_cross.gif)
70. Okumura Y, Yokoyama K, Matsumoto N, et al. Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry. J Arrhythm. 2017; 33:289–296.
![crossref](/image/icon/bnr_ref_cross.gif)
71. Wang KL, Giugliano RP, Goto S, et al. Standard dose versus low dose non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: a meta-analysis of contemporary randomized controlled trials. Heart Rhythm. 2016; 13:2340–2347.
![crossref](/image/icon/bnr_ref_cross.gif)
72. Holmes DR, Reddy VY, Turi ZG, PROTECT AF Investigators, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374:534–542.
![crossref](/image/icon/bnr_ref_cross.gif)
73. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014; 64:1–12.
74. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017; 70:2964–2975.
75. Lam YY, Yip GW, Yu CM, et al. Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience. Catheter Cardiovasc Interv. 2012; 79:794–800.
![crossref](/image/icon/bnr_ref_cross.gif)
76. Lee OH, Kim JS, Pak HN, et al. Feasibility of left atrial appendage occlusion for left atrial appendage thrombus in patients with persistent atrial fibrillation. Am J Cardiol. 2018; 121:1534–1539.
![crossref](/image/icon/bnr_ref_cross.gif)
77. Kim JS, Lee H, Suh Y, et al. Left atrial appendage occlusion in non-valvular atrial fibrillation in a Korean Multi-Center Registry. Circ J. 2016; 80:1123–1130.
![crossref](/image/icon/bnr_ref_cross.gif)
78. Chen Y, Zhang Y, Huang W, Huang K, Xu B, Su XI. Primary and secondary stroke prevention using left atrial appendage closure with Watchman devices in atrial fibrillation patients: a single center experience from Mainland China. Pacing Clin Electrophysiol. 2017; 40:607–614.
79. Landmesser U, Schmidt B, Nielsen-Kudsk JE, et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention. 2017; 13:867–876.
![crossref](/image/icon/bnr_ref_cross.gif)
80. Phan QT, Shin SY, Cho IS, et al. Impact of left atrial appendage closure on cardiac functional and structural remodeling: a Difference-in-Difference analysis of propensity score matched samples. Cardiol J. 2018.
![crossref](/image/icon/bnr_ref_cross.gif)
81. Siu CW, Tse HF. Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2014; 7:300–306.
![crossref](/image/icon/bnr_ref_cross.gif)
82. Huisman MV, Rothman KJ, Paquette M, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, Phase II. Am J Med. 2015; 128:1306–1313.e1.
![crossref](/image/icon/bnr_ref_cross.gif)
83. Bassand JP, Accetta G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016; 37:2882–2889.
![crossref](/image/icon/bnr_ref_cross.gif)
84. Guo Y, Wang H, Tian Y, Wang Y, Lip GY. Time trends of aspirin and warfarin use on stroke and bleeding events in Chinese patients with new-onset atrial fibrillation. Chest. 2015; 148:62–72.
![crossref](/image/icon/bnr_ref_cross.gif)
85. Chang SS, Dong JZ, Ma CS, et al. Current status and time trends of oral anticoagulation use among Chinese patients with nonvalvular atrial fibrillation: the Chinese atrial fibrillation registry study. Stroke. 2016; 47:1803–1810.
86. Siu CW, Lip GY, Lam KF, et al. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm. 2014; 11:1401–1408.
![crossref](/image/icon/bnr_ref_cross.gif)
87. Son MK, Lim NK, Park HY. Trend of prevalence of atrial fibrillation and use of oral anticoagulation therapy in patients with atrial fibrillation in South Korea (2002–2013). J Epidemiol. 2018; 28:81–87.
![crossref](/image/icon/bnr_ref_cross.gif)
88. Lee SR, Choi EK, Han KD, Cha MJ, Oh S, Lip GY. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: a nationwide population-based study. PLoS One. 2017; 12:e0189495.
![crossref](/image/icon/bnr_ref_cross.gif)
89. Lee SR, Han K, Cha MJ, et al. Prevalence of non-valvular atrial fibrillation based on geographical distribution and socioeconomic status in the entire Korean population. Korean Circ J. 2018; 48:e58.
![crossref](/image/icon/bnr_ref_cross.gif)
90. Kim H, Kim TH, Cha MJ, et al. A prospective survey of atrial fibrillation management for real-world guideline adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry. Korean Circ J. 2017; 47:877–887.
![crossref](/image/icon/bnr_ref_cross.gif)
91. Suzuki S, Otsuka T, Sagara K, et al. Nine-year trend of anticoagulation use, thromboembolic events, and major bleeding in patients with non-valvular atrial fibrillation - Shinken Database analysis. Circ J. 2016; 80:639–649.
92. Miyazaki S, Miyauchi K, Hayashi H, et al. Registry of Japanese patients with atrial fibrillation focused on anticoagulant therapy in the new era: The RAFFINE registry study design and baseline characteristics. J Cardiol. 2018; 71:590–596.
![crossref](/image/icon/bnr_ref_cross.gif)
93. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest. 2013; 144:1555–1563.
94. Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013; 2:e000067.
![crossref](/image/icon/bnr_ref_cross.gif)
95. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376:975–983.
![crossref](/image/icon/bnr_ref_cross.gif)
96. Oh S, Goto S, Accetta G, et al. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. Int J Cardiol. 2016; 223:543–547.
![crossref](/image/icon/bnr_ref_cross.gif)
97. Bernaitis N, Ching CK, Chen L, et al. The sex, age, medical history, treatment, tobacco use, race risk (SAMe TT2R2) score predicts warfarin control in a Singaporean population. J Stroke Cerebrovasc Dis. 2017; 26:64–69.
98. Hong KS, Kim YK, Bae HJ, et al. Quality of anticoagulation with warfarin in Korean patients with atrial fibrillation and prior stroke: a multicenter retrospective observational study. J Clin Neurol. 2017; 13:273–280.
![crossref](/image/icon/bnr_ref_cross.gif)
99. Saokaew S, Sapoo U, Nathisuwan S, Chaiyakunapruk N, Permsuwan U. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm. 2012; 34:105–112.
![crossref](/image/icon/bnr_ref_cross.gif)
100. Thanimalai S, Shafie AA, Hassali MA, Sinnadurai J. Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital. Int J Clin Pharm. 2013; 35:736–743.
![crossref](/image/icon/bnr_ref_cross.gif)
101. Bernaitis N, Ching CK, Teo SC, et al. Factors influencing warfarin control in Australia and Singapore. Thromb Res. 2017; 157:120–125.
![crossref](/image/icon/bnr_ref_cross.gif)
102. Yang QD, Niu Q, Zhou YH, et al. Incidence of cerebral hemorrhage in the Changsha community. A prospective study from 1986 to 2000. Cerebrovasc Dis. 2004; 17:303–313.
103. Guo Y, Pisters R, Apostolakis S, et al. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact? Int J Cardiol. 2013; 168:515–522.
![crossref](/image/icon/bnr_ref_cross.gif)
104. Gamra H, Murin J, Chiang CE, et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis. 2014; 107:77–87.
![crossref](/image/icon/bnr_ref_cross.gif)
105. Huisman MV, Ma CS, Diener HC, et al. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace. 2016; 18:1308–1318.
![crossref](/image/icon/bnr_ref_cross.gif)
106. Amerena J, Chen SA, Sriratanasathavorn C, et al. Insights into management of atrial fibrillation in Asia Pacific gained from baseline data from REgistry on cardiac rhythm disORDers (RecordAF-Asia Pacific [AP]) registry. Am J Cardiol. 2012; 109:378–382.
![crossref](/image/icon/bnr_ref_cross.gif)
107. Chang CH, Yang YH, Chen JH, Lin LJ. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan. Thromb Res. 2014; 133:782–789.
![crossref](/image/icon/bnr_ref_cross.gif)
108. Chan EW, Lau WC, Siu CW, et al. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: a population-wide cohort study. Heart Rhythm. 2016; 13:1581–1588.
![crossref](/image/icon/bnr_ref_cross.gif)
109. Chao TF, Liu CJ, Lin YJ, et al. Oral anticoagulation in very elderly patients with atrial fibrillation - a nationwide cohort study. Circulation. 2018.
110. Bai Y, Guo SD, Deng H, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age Ageing. 2018; 47:9–17.
![crossref](/image/icon/bnr_ref_cross.gif)
111. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006; 37:447–451.
112. Yasaka M, Lip GY. Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation. Circ J. 2014; 78:2367–2372.
![crossref](/image/icon/bnr_ref_cross.gif)
113. Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost. 2016; 115:31–39.
114. Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016; 5:e003074.
![crossref](/image/icon/bnr_ref_cross.gif)
115. Bai Y, Wang YL, Shantsila A, Lip GY. The global burden of atrial fibrillation and stroke: a systematic review of the clinical epidemiology of atrial fibrillation in Asia. Chest. 2017; 152:810–820.
116. Bai Y, Guo SD, Shantsila A, Lip GY. Modelling projections for the risks related with atrial fibrillation in East Asia: a focus on ischaemic stroke and death. Europace. 2017.
![crossref](/image/icon/bnr_ref_cross.gif)
117. Lip GY. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017; 14:627–628.
![crossref](/image/icon/bnr_ref_cross.gif)
118. Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017; 117:1230–1239.
119. Fauchier L, Villejoubert O, Clementy N, et al. Causes of death and influencing factors in patients with atrial fibrillation. Am J Med. 2016; 129:1278–1287.
![crossref](/image/icon/bnr_ref_cross.gif)
120. Pokorney SD, Piccini JP, Stevens SR, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc. 2016; 5:e002197.